<code id='F0800B719D'></code><style id='F0800B719D'></style>
    • <acronym id='F0800B719D'></acronym>
      <center id='F0800B719D'><center id='F0800B719D'><tfoot id='F0800B719D'></tfoot></center><abbr id='F0800B719D'><dir id='F0800B719D'><tfoot id='F0800B719D'></tfoot><noframes id='F0800B719D'>

    • <optgroup id='F0800B719D'><strike id='F0800B719D'><sup id='F0800B719D'></sup></strike><code id='F0800B719D'></code></optgroup>
        1. <b id='F0800B719D'><label id='F0800B719D'><select id='F0800B719D'><dt id='F0800B719D'><span id='F0800B719D'></span></dt></select></label></b><u id='F0800B719D'></u>
          <i id='F0800B719D'><strike id='F0800B719D'><tt id='F0800B719D'><pre id='F0800B719D'></pre></tt></strike></i>

          hotspot

          hotspot

          author:focus    Page View:1464
          Cambridge: Biogen
          Ruby Wallau for STAT

          Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

          The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

          advertisement

          HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more
          Supreme Court mifepristone arguments center on docs' right to sue
          Supreme Court mifepristone arguments center on docs' right to sue

          Abortion-rightsactivistsarearrestedbyU.S.CapitolpoliceastheirprotestoutsideoftheSupremeCourtduringar

          read more
          Wildfire smoke exposes gaps in outdoor worker protections
          Wildfire smoke exposes gaps in outdoor worker protections

          ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

          read more

          UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

          PATRICKT.FALLON/AFPviaGettyImagesUnitedHealthGrouphasmadeitclearthatmorepeople,especiallyolderadults